

Evonik and InVitria partner to expand access to animal-free albumin for biopharma innovation

- Expanded supply of animal component-free human serum albumin for advanced therapies and next-generation biopharmaceutical processes
- Safer, more consistent raw materials that support improved process efficiency and product stability
- Portfolio expansion of recombinant proteins strengthens Evonik's Precision Biosolutions

Essen, Germany. Evonik has entered a strategic partnership with InVitria, a leading developer of recombinant proteins and supplements, to supply animal component-free (ACF) recombinant human serum albumin to the global biopharmaceutical industry. The collaboration brings together Evonik's global reach and expertise in cell culture ingredients with InVitria's advanced recombinant production technology. It also enables more customers to access high-quality, animal-free ingredients that enhance process efficiency and product stability across cell culture and biologics formulations.

"By combining our expertise in cell culture and parenteral drug product solutions with InVitria's innovative recombinant technologies, we are well positioned to support the development of highly innovative biopharmaceuticals. This collaboration is the starting point for Evonik's future growth in recombinant proteins," said Guido Skudlarek, head of the Health Care business line.

Evonik will distribute InVitria's blood-free recombinant human serum albumin (rHSA) portfolio to its biopharma customers. InVitria's rHSA is a highly pure recombinant version of albumin – a key protein used to stabilize, protect, and transport molecules in drug development. InVitria's rHSA is expressed in a non-mammalian host, eliminating reliance on animal- or human-derived serum proteins. This avoids the risks of contamination, supply limitations, and batch variability. The result is a safer, more consistent ingredient that supports improved process efficiency and product stability across a wide range of

November 17, 2025

Main press contact

Janusz Berger

Head of Market Communications
Health Care
Phone + 49 6151 18-4984
janusz.berger@evonik.com

Alternative press contact

Dr. Jürgen Krauter

Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Lauren Kjeldsen
Dr. Claudine Mollenkopf
Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

biopharmaceutical applications such as cell culture, gene therapy, vaccine development or regenerative medicine.

"This collaboration strengthens our shared commitment to providing reliable, animal-origin-free protein solutions that enhance process efficiency, ensure product quality, and accelerate innovation across the life sciences," said Scott Deeter, CEO of InVitria.

The market for recombinant human serum albumin is projected to grow nearly 10 percent (CAGR) from 2025 to 2033. This growth is fuelled by a demand for safe animal-free protein alternatives in the biopharmaceutical industry.

InVitria's products are used by innovators developing vaccines, biologics, cell and gene therapies, and regenerative medicine. This sustainable, non-animal approach reduces risk, improves consistency, and supports scalability.

Evonik is strengthening the innovation pipeline of pharmaceutical and biopharmaceutical companies through its strategic focus on Advance Precision Biosolutions. rHSA supports different kinds of bioprocessing that can be used in various biosolutions. Building on its collaboration with InVitria, Evonik plans to expand its recombinant protein portfolio and therefore contribute to the growth of the company's Precision Biosolutions. With over 60 years of experience, Evonik offers a comprehensive portfolio of high-quality cell culture ingredients – including amino acids, peptides, and plant-based lipids – designed to meet the evolving needs of biopharma.

Further Information

About InVitria: <https://invitria.com/>

Learn more about biopharma and bioprocessing at Evonik:
https://www.evonik.com/en/applications/application_1659050.html

Market insights for recombinant human serum albumin taken from Global Growth Insights: Recombinant Human Serum Albumin Market Size & Growth, Forecast 2025–2033 [Accessed 3 Nov 2025]

Evonik: Leading beyond chemistry

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.

About Custom Solutions

The Custom Solutions segment focuses on innovation-driven, tailor-made solutions for customers in specific growth markets. These solutions include additives for coatings, adhesives and sealants, polyurethane foams and lubricants, catalysts, and ingredients for the cosmetics, cleaning and pharmaceutical industries. In 2024, the segment generated sales of €5.7 billion with around 7,000 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.